Dr. Vivash Naidoo

Vivash Naidoo is a biomedical researcher whose work spans molecular pharmacology, toxicology, and translational cancer biology. Earlier research explored synergistic interactions between dietary iron, aflatoxin B1, and alcohol in hepatic mutagenesis, clarifying mechanisms of oxidative DNA damage and hepatocarcinogenesis. Contributions to microbiome–metabolome studies further reflect engagement with diet-related cancer risk and systems-level analysis of disease.

More recent studies focus on targeted therapeutics and signal transduction in oncology. Investigations of EGFR inhibition in colorectal cancer highlight modulation of apoptotic regulators such as BCL-2, BAX, and p53, supporting the development of novel small molecules with translational promise. Work on advanced BRET-based biosensors in glioblastoma models demonstrates expertise in live-cell signaling, GPCR pathways, and precision-oriented molecular communication.

Parallel research in phytomedicine examines plant-derived therapies for benign prostatic hyperplasia and metabolic disorders, evaluating efficacy and safety in preclinical models. This portfolio underscores strengths in experimental design, mechanistic insight, and integration of natural products with conventional pharmacology, positioning Naidoo at the intersection of cancer therapeutics, toxicological mechanisms, and complementary medicine research.